Abstract
Influenza A(H1N1)pdm09 and A(H3N2) viruses both circulated in Europe in October 2018-January 2019. Interim results from six studies indicate that 2018/19 influenza vaccine effectiveness (VE) estimates among all ages in primary care was 32-43% against influenza A; higher against A(H1N1)pdm09 and lower against A(H3N2). Among hospitalised older adults, VE estimates were 34-38% against influenza A and slightly lower against A(H1N1)pdm09. Influenza vaccination is of continued benefit during the ongoing 2018/19 influenza season.
Keywords:
Europe; influenza; multicentre study; test-negative design; vaccination; vaccine effectiveness; vaccines and immunisation.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Case-Control Studies
-
Child
-
Europe / epidemiology
-
Female
-
Humans
-
Influenza A Virus, H1N1 Subtype / immunology*
-
Influenza A Virus, H1N1 Subtype / isolation & purification
-
Influenza A Virus, H3N2 Subtype / immunology*
-
Influenza A Virus, H3N2 Subtype / isolation & purification
-
Influenza B virus / immunology*
-
Influenza B virus / isolation & purification
-
Influenza Vaccines / administration & dosage
-
Influenza Vaccines / immunology*
-
Influenza, Human / epidemiology
-
Influenza, Human / prevention & control*
-
Influenza, Human / virology
-
Male
-
Middle Aged
-
Outcome Assessment, Health Care*
-
Population Surveillance
-
Primary Health Care
-
Reverse Transcriptase Polymerase Chain Reaction
-
Seasons
-
Sensitivity and Specificity
-
Vaccination / statistics & numerical data
-
Vaccine Potency*